cyclopentolate
ApprovedSmall molecule
cyclopentolate is one of 52 small molecule programs targeting Myopia. It is currently in Approved.
3
Indications
5
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Pred Forte
NovartisPhase 3
Bayer Aspirin
BayerPhase 3
Lotemax
BBausch & Lomb Incorporated
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
cyclopentolate
KKK Women's and Children's Hospital
Approved
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Children1 trial
Cycloplegic Refraction Among Children
Completed·—·Phase 4·NCT05442801·55 enrolled
Esotropia1 trial
Cycloplegic Refraction in Pediatric Patients With Esotropia
Unknown status·—·Phase 4·NCT06077682·100 enrolled
Cataract1 trial
Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery
Unknown status·—·Phase 2·NCT03851172·75 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cyclopentolate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details